Table 1.
Study characteristics.
| Item | Number of studies (N. of data) | Number of participants (mean ± SD) | |||
|---|---|---|---|---|---|
| Male | Female | No information | Total | ||
| Total | 57 (151) | 11,805 (268 ± 407) | 22,505 (417 ± 583) | – | 34,310 (6,02 ± 869)a |
| Cross-sectional study | 38 (99) | 7651 (247 ± 334) | 14,505 (403 ± 574) | – | 22,156 (583 ± 804) |
| Longitudinal study | 19 (52) | 4154 (320 ± 557) | 8000 (444 ± 617) | – | 12,154 (640 ± 1010) |
| Severity classificationb | |||||
| Single | 25 (93) | 9874 | 17,430 | 12,516 | 39,820 |
| Binary | 12 (21) | 1908 | 3853 | 0 | 5761 |
| Trinomial | 23 (37) | 4011 | 11,770 | 199 | 15,980 |
| Type of cancer | |||||
| Breast | 24 (30) | 2 | 14,634 | 0 | 14,636 |
| Urologic | 12 (17) | 2338 | 0 | 314 | 2652 |
| Gastrointestinal | 12 (14) | 1019 | 888 | 1223 | 3130 |
| Hematologic | 10 (13) | 2553 | 2190 | 1486 | 6229 |
| Lung | 7 (8) | 907 | 614 | 797 | 2318 |
| Gynecologic | 4 (6) | 0 | 3061 | 0 | 3061 |
| Head and neck | 3 (4) | 138 | 194 | 151 | 483 |
| Brain | 3 (4) | 30 | 88 | 355 | 473 |
| Regardless of cancer type | 23 (55) | 6007 | 9086 | 13,486 | 28,579 |
| Cancer status | |||||
| Cancer present | 44 (109) | 7263 | 16,637 | 13,461 | 37,361 |
| Cancer-free | 14 (26) | 2542 | 5540 | 3424 | 11,506 |
| Not defined | 5 (16) | 3928 | 7202 | 1564 | 12,694 |
| Treatment phase | |||||
| Before treatment | 11 (14) | 1252 | 2286 | 65 | 3603 |
| Ongoing treatment | 22 (45) | 3343 | 9007 | 4208 | 16,558 |
| After treatment | 11 (30) | 1342 | 3556 | 6868 | 11,766 |
| Type of treatment | |||||
| Chemotherapy | 14 (15) | 2203 | 3765 | 1780 | 7748 |
| Surgery | 11 (13) | 240 | 3615 | 2551 | 6406 |
| Radiotherapy | 11 (13) | 386 | 2471 | 1678 | 4535 |
| Endocrine therapy | 9 (10) | 253 | 1418 | 1413 | 3084 |
| Targeted therapy | 3 (3) | 0 | 0 | 202 | 202 |
| Stem cell transplantation | 1 (1) | 57 | 41 | 0 | 98 |
| Regardless of treatment type | 30 (82) | 10,030 | 17,282 | 8573 | 35,885 |
| No treatment | 11 (14) | 1252 | 2286 | 65 | 3603 |
| Assessment method | |||||
| Self-reported | 56 (149) | 15,793 | 30,725 | 12,715 | 59,233 |
| Physician diagnosis | 1 (2) | 0 | 2328 | 0 | 2328 |
| Assessment toolc | |||||
| BFI | 17 (29) | 2227 | 8804 | 145 | 11,176 |
| CIS | 7 (25) | 384 | 594 | 465 | 1443 |
| EORTC QLQ-C30 | 5 (23) | 6966 | 10,534 | 4908 | 22,408 |
| MDSAI | 6 (22) | 2202 | 4769 | 5593 | 12,564 |
| MFI-20 | 6 (19) | 1414 | 2086 | 1604 | 5104 |
| FSS | 4 (8) | 316 | 186 | 0 | 502 |
| PFS | 4 (4) | 85 | 1306 | 0 | 1391 |
| Others (9 tools)d | 9 (21) | 2199 | 4774 | 0 | 6973 |
| Continent | |||||
| Europe | 25 (77) | 10,666 | 15,110 | 5373 | 31,149 |
| North America | 13 (38) | 2658 | 10,935 | 5738 | 19,331 |
| Asia | 12 (24) | 1804 | 3730 | 1604 | 7138 |
| Oceania | 2 (5) | 321 | 531 | 0 | 852 |
| South America | 3 (3) | 146 | 315 | 0 | 461 |
| Worldwide | 2 (3) | 176 | 2432 | 0 | 2608 |
| Publication year | |||||
| Until 2010 | 16 (39) | 5377 | 12,301 | 32 | 17,710 |
| After 2010 | 41 (112) | 10,416 | 20,752 | 12,683 | 43,851 |
aTotal number of participants based on 50 studies, while sum of participants in subgroups is larger due to coming from each prevalence data.
bSingle: severe, moderate to severe, strong; Binary: high/very high, moderate/severe, mild/moderate to intense, mild/moderate to severe; Trinomial: mild/moderate/severe, a little/quite a bit/very much, minor/moderate/severe, moderate/severe/very severe.
cCIS, Checklist Individual Strength; EORTC QLQ‐C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30; BFI, Brief Fatigue Inventory; MDSAI, M. D. Anderson Symptom Inventory; MFI-20, Multidimensional Fatigue Inventory; FSS, Fatigue Severity Scale; PFS, Piper Fatigue Scale.
dCTCAE, Common Terminology Criteria for Adverse Event (ver. 3); National Comprehensive Cancer Network (NCCN) fatigue screening; RSCL, Rotterdam Symptom Checklist.